Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own0.40% Shs Outstand160.34M Perf Week3.59%
Market Cap20.39B Forward P/E- EPS next Y-1.53 Insider Trans-34.99% Shs Float160.08M Perf Month3.45%
Income-163.40M PEG- EPS next Q-0.53 Inst Own99.40% Short Float2.58% Perf Quarter17.95%
Sales802.80M P/S25.40 EPS this Y28.10% Inst Trans6.28% Short Ratio2.67 Perf Half Y49.49%
Book/sh15.39 P/B8.26 EPS next Y28.80% ROA-6.00% Target Price131.11 Perf Year126.32%
Cash/sh6.29 P/C20.22 EPS next 5Y25.00% ROE-9.40% 52W Range55.36 - 133.54 Perf YTD40.70%
Dividend- P/FCF- EPS past 5Y37.13% ROI-4.70% 52W High-4.76% Beta0.70
Dividend %- Quick Ratio4.30 Sales past 5Y18.30% Gross Margin82.60% 52W Low129.75% ATR3.76
Employees1681 Current Ratio5.00 Sales Q/Q34.10% Oper. Margin-24.30% RSI (14)64.07 Volatility2.87% 3.65%
OptionableYes Debt/Eq0.27 EPS Q/Q-65.40% Profit Margin-20.40% Rel Volume0.50 Prev Close126.88
ShortableYes LT Debt/Eq0.27 EarningsApr 30 AMC Payout- Avg Volume1.55M Price127.19
Recom1.70 SMA205.87% SMA504.70% SMA20035.19% Volume773,270 Change0.24%
May-01-15Reiterated JP Morgan Overweight $120 → $125
Mar-27-15Reiterated UBS Buy $112 → $136
Mar-27-15Reiterated Deutsche Bank Buy $90 → $140
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Sep-18-13Downgrade Stifel Buy → Hold
Jul-26-13Reiterated Stifel Buy $67 → $70
Apr-03-13Reiterated Barclays Overweight $54 → $70
Mar-20-13Reiterated RBC Capital Mkts Outperform $58 → $64
Mar-20-13Reiterated Deutsche Bank Hold $45 → $59
Feb-22-13Reiterated RBC Capital Mkts Outperform $55 → $58
Feb-01-13Reiterated UBS Buy $53 → $67
Jan-22-13Upgrade Stifel Nicolaus Hold → Buy $67
Nov-06-12Reiterated Barclays Overweight $46 → $54
May-22-15 06:00PM  Cramer shuts down this market's haters
May-21-15 05:24PM  Biotech stock set to double
12:38AM  Sareptas Feast May Not Satisfy at The Wall Street Journal
May-20-15 08:59PM  Sarepta Gets FDA Green Light to Submit Application at Investopedia
05:14PM  Sarepta's Feast May Not Satisfy at The Wall Street Journal
May-19-15 04:42PM  FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug! at TheStreet
May-10-15 11:00AM  These biotech names are ripe for mergers: Analysts at CNBC
May-07-15 08:09PM  10-Q for BioMarin Pharmaceutical, Inc. at Company Spotlight
08:38AM  BioMarin Pharmaceutical (BMRN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
08:30AM  Why These 4 Biotech Stocks Could Be the Next Buyout Targets at 24/7 Wall St.
May-06-15 05:26PM  Biotech takeover targets +5.07%
10:24AM  Why BioMarin's New Drug Application is Good News for Sarepta Therapuetics at Barrons.com
10:07AM  Rare disease stocks fly on Alexion acquisition
09:20AM  Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review
May-05-15 02:32PM  Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. at Barrons.com
11:41AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
May-04-15 12:40PM  Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog
10:22AM  No, the Biotech Boom Isn't Over at Barrons.com
May-01-15 09:55AM  BioMarin Q1 Loss Narrower than Expected, '15 View Revised - Analyst Blog
08:54AM  BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th at noodls
08:00AM  BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th GlobeNewswire
05:11AM  BioMarin Pharmaceutical (BMRN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
Apr-30-15 04:51PM  BioMarin reports 1Q loss
04:30PM  Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today
04:17PM  BioMarin Announces First Quarter 2015 Financial Results and Company Update at noodls
04:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  BioMarin Announces First Quarter 2015 Financial Results and Company Update GlobeNewswire
07:07AM  Q1 2015 Biomarin Pharmaceutical Inc Earnings Release - After Market Close
Apr-29-15 04:32PM  BioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog
01:55PM  Can Expedia (EXPE) Pull a Surprise this Earnings Season? - Analyst Blog
09:30AM  Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Apr-28-15 04:10PM  Will BioMarin (BMRN) Top Earnings Again on Vimzim Sales? - Analyst Blog
12:09PM  Here's What's Next as BioMarin Moves Closer to Duchenne Drug Approval at TheStreet
09:19AM  BioMarin Pharmaceutical (BRMN) Stock Rises After CEO Appears on Jim Cramer's 'Mad Money' at TheStreet
06:00AM  Jim Cramer's Top Takeaways: Intel, Restoration Hardware, BioMarin Pharmaceuticals at TheStreet
Apr-27-15 07:58PM  [video]Jim Cramer's 'Mad Money' Recap: Market Squall Making Me Seasick at TheStreet
07:10PM  Cramer Remix: My take on Apple's massive earnings at CNBC
04:59PM  Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog
09:58AM  BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping at noodls
09:42AM  BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
Apr-24-15 12:05PM  Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results at TheStreet
Apr-23-15 05:18PM  BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting at noodls
04:51PM  BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting GlobeNewswire
10:01AM  Santhera -- A Duchenne Drug With Positive Study Results That Few Know About at TheStreet
Apr-21-15 04:41PM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) at noodls
04:10PM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
02:32PM  Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No at Barrons.com
Apr-14-15 08:19AM  BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET at noodls
08:00AM  BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET GlobeNewswire
Apr-10-15 11:41AM  Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but Net Returns Were Only 5% Heres Why at Insider Monkey
10:00AM  The Oprahs Of Biotech: People Who Can Go By First Name Only at Forbes
Apr-09-15 09:30AM  Billionaire John Griffins Five Picks That Killed the Market This Quarter at Insider Monkey
Apr-06-15 05:20PM  Biotech Stocks Still Feeling Healthy Despite Bubble Talk at TheStreet
Apr-03-15 02:37PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits
Apr-02-15 12:33PM  Retrophin Hits High On Bullish Initiation Report at Investor's Business Daily
Apr-01-15 06:36PM  Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog
Mar-31-15 09:57PM  Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame at TheStreet
11:51AM  Biotech's next buzz: Gene therapy? at CNBC
07:53AM  How bubbles are blown: Biotech edition
Mar-30-15 06:58PM  Cramer tackles a tough tweet
09:26AM  BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting at noodls
09:00AM  BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting GlobeNewswire
08:51AM  BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape
Mar-27-15 06:40PM  BioMarin Pharma Hits All-Time High at Investor's Business Daily +11.45%
06:25PM  Four horsemen of semis & biotech: Cramer
05:54PM  BioMarin jumps after analyst suggests merger may be in its future at MarketWatch
04:46PM  Shire shines on fourth day of FTSE falls at Financial Times
04:28PM  Equities snapped its four day losing streak...
04:11PM  Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks Amici Capital Is Bullish on at Insider Monkey
03:44PM  BioMarin Pharmaceutical (BMRN) Stock Gains Today on Merger Rumors at TheStreet
02:30PM  Street Talk: Zayo Group under the radar
08:35AM  RBC Has 4 Biotech Stocks to Buy After Massive Pullback at 24/7 Wall St.
Mar-26-15 12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
Mar-25-15 10:03AM  Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)s 18% Spike at Insider Monkey -6.00%
Mar-24-15 06:28AM  Profit takers active as biotech stalls
Mar-23-15 08:50AM  Cramer's stocks to watch: Amazing biotech
08:33AM  Biotech's path to discovery: BioMarin CEO
Mar-18-15 04:30PM  Biotech Bull Market: The Two Best Ways to Play It at Barrons.com
02:10PM  How the Weaker Euro Is Impacting Biotech Earnings at 24/7 Wall St.
08:00AM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-16-15 06:17PM  Cramer: This sector has tons of hidden opportunity at CNBC
08:51AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Moves Up 6.9% - Tale of the Tape
Mar-13-15 12:17PM  Short Sellers Still Attracted To Biotech Stocks +6.86%
Mar-12-15 08:07PM  Lightning Round: Good chance this is downgraded at CNBC
Mar-11-15 12:04PM  18 Biotech Stocks These Wall Street Analysts Are Tracking
Mar-10-15 03:17PM  United Therapeutics Wins FDA Nod, Priority Voucher at Investor's Business Daily
Mar-06-15 03:24PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers
08:20AM  The Next 3 Likely Biotech Buyout Candidates at 24/7 Wall St.
Mar-05-15 07:08PM  10-K for BioMarin Pharmaceutical, Inc. at Company Spotlight
06:13PM  Cramer: This X factor is ignored in your portfolio at CNBC
04:02PM  Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst
Mar-03-15 10:09AM  BioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management at Insider Monkey
Feb-27-15 10:10AM  Company News for February 27, 2015 - Corporate Summary
09:30AM  Cowen Raises Price Targets on Top Momentum Stocks at 24/7 Wall St.
Feb-26-15 11:50AM  Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Zacks
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog Zacks
09:50AM  BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Zacks
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FUCHS HENRY JEVP, Chief Medical OfficerMay 18Sale124.781,864232,58476,746May 19 07:21 PM
Davis George EricSVP, General CounselMay 18Sale125.262,558320,41569,226May 19 07:18 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale121.371,434174,03880,646May 14 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 11Sale121.642,869348,98883,646May 12 07:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Option Exercise33.9333,6311,141,21576,664May 08 05:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Sale119.1434,0194,053,04242,645May 08 05:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise6.4623,218149,98856,476May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.9823,2182,669,51733,258May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.983,505402,992248,654May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Option Exercise6.4622,546145,64755,804Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.5322,5462,717,54633,258Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.533,506422,590251,251Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 20Sale126.401,000126,39633,258Mar 24 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 17Sale124.871,000124,86634,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Option Exercise21.5140,000860,400129,950Mar 18 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale123.481,000123,47735,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Sale123.5741,3155,105,16688,635Mar 18 07:50 PM
Davis George EricSVP, General CounselMar 13Option Exercise37.0815,000556,23988,846Mar 17 06:03 PM
Davis George EricSVP, General CounselMar 13Sale120.8715,0001,813,00273,846Mar 17 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale114.892,021232,20136,258Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise12.9915,000194,85057,279Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale112.1319,0002,130,38338,279Mar 11 06:32 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 03Sale69.77181,25668,733Feb 10 12:57 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM